Abstract. Cell division cycle 20 (CDC20) is a regulatory molecule and serves critical roles at multiple points of the cell cycle. Recent evidence indicates that CDC20 may serve an oncogenic role in a number of human cancer types. However, the role of CDC20 in primary cutaneous squamous cell carcinoma (cSCC) has not been studied, to the best of our knowledge. The aim of the present study was to investigate whether and how CDC20 is involved in the tumorigenesis of cSCC. The results revealed that CDC20 expression was significantly increased in cSCC tissues and cell lines, and its expression was associated with pathological differentiation. Downregulation of CDC20 inhibited cell proliferation, induced cell cycle arrest, promoted apoptosis and reduced migratory ability through inhibition of the Wnt/β-catenin signaling pathway. Furthermore, all-trans-retinoic acid treatment significantly downregulated CDC20 expression in cSCC. The present results revealed that CDC20 may serve a crucial role in human cSCC, and suggested that CDC20 may be a novel biomarker for the prevention, diagnosis and treatment of cSCC.
Introduction
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of non-melanoma skin cancer, with an annual global incidence exceeding 1 million (1). Although the majority of patients with cSCC have a good prognosis following appropriate therapy, 5-10% of cases have very poor outcomes, which include local recurrence, nodal metastasis and disease-specific mortality (2) (3) (4) . Given the frequency of its occurrence, cSCC is reported to cause as many annual mortalities as melanoma in the USA (5) . However, there are few reliable biomarkers to predict the biological behavior and clinical outcome of cSCC. Therefore, the identification of biomarkers along with a better understanding of the molecular mechanisms of cSCC is urgently required for the development of effective treatments for the disease.
Cell division cycle 20 (CDC20) is a key molecule that serves an important role in the cell cycle, including as a spindle assembly checkpoint and as an activator of the anaphase-promoting complex (APC/C) (6) . APC/Ccdc20 serves a crucial role during the metaphase to anaphase transition, in addition to mitotic exit, through the destruction of various critical cell cycle regulators (7) . In addition to regulating the cell cycle, evidence has demonstrated that CDC20 serves an important role in human tumorigenesis and cancer progression (8) . Abnormal expression of CDC20 may disorder APC/C activation and promote premature anaphase, which frequently results in mitotic abnormalities and aneuploidy in the two daughter cells (8) . Overexpression of CDC20 has been observed in a variety of human tumors, including lung cancer, gastric cancer and breast cancer. Its activity is reported to be critical for tumor initiation, maintenance and growth (9) (10) (11) (12) (13) (14) (15) (16) (17) . However, CDC20 expression and its clinical significance in human cSCC has not been previously studied, to the best of our knowledge.
The present study detected the expression of CDC20 in cSCC patient samples at different stages. Its biological functions were also investigated through a gene knockdown approach in vitro. The present results suggested that CDC20 expression was positively correlated with the progression of cSCC, and that the loss of CDC20 suppressed cell growth and migration, but induced apoptosis and cell cycle arrest in cSCC cells through inhibition of the wnt/β-catenin signaling pathway. In addition, the present findings demonstrated that all-trans-retinoic acid (ATRA) treatment downregulated CDC20 expression in cSCC cells.
CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the Wnt/β-catenin signaling pathway Materials and methods
Bioinformatics analyses. The cSCC mRNA expression microarray datasets GSE32628 and GSE45216 were downloaded from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo) (18, 19 Table I . A431 and SCL-1 cells were seeded in 6-well/96-well plates and transfected with 100 pmol/10 pmol siRNA, respectively, the following day, according to the recommended procedures for Lipofectamine ® 2000 Transfection Reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The CDC20 expression plasmid (HA-CDC20; cat. no. 11594) and the empty control expression plasmid (pCS2P+; cat. no. 17095), which had the same backbone as the CDC20 expression construct, were purchased from Addgene, Inc. (Cambridge, MA, USA). SCC13 cells were seeded in 6-well/96-well plates and transfected with plasmid the following day. Plasmid DNA was diluted in OptiMEM (Gibco; Thermo Fisher Scientific, Inc.) and combined with 1 µg/ml polyethylenimine (PEI) in a 1:3 ratio (DNA:PEI). The PEI/DNA mix was added in a dropwise manner to the cells, and they were incubated for 12 h. The DMEM was refreshed and the cells were harvested or counted after 72 h. Cells treated with the transfection reagent only acted as the mock transfection control.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RNA samples were isolated using the TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed to cDNA using the PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan). The reaction conditions were 37˚C for 15 min and 85˚C for 5 sec, followed by rapid cooling to 4˚C and storage at -20˚C. The CDC20 mRNA levels in each group were detected using SYBR Premix Ex Taq (Takara Bio, Inc.) on a StepOnePlus™ Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The cycling conditions were: 95˚C for 30 sec, followed by 40 cycles at 95˚C for 5 sec and 60˚C for 30 sec. The gene expression levels were calculated using the 2 -ΔΔCq method (21) and each experiment was repeated three times. The primer sequences were as follows: CDC20 (forward, 5'-GACCACTCCTAGCAAACC TGG-3' and reverse, 5'-GGGCGTCTGGCTGTTTTCA-3') and GAPDH (forward, 5'-ACCACAGTCCATGCCATCAC-3' and reverse, 5'-TCCACCACCCTGTTGCTGTA-3').
Western blotting. Total cellular proteins were extracted from the cultured cells using lysis buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 50 mM NaF, 1 mM EDTA and 10 mM β-glycerol-P]. The protein concentration was determined using a Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Subsequently, 40 µg proteins were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Following blocking with non-fat dried milk for 2 h at room temperature, the membranes were incubated overnight with primary antibodies at 4˚C and subsequently incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (anti-Rabbit IgG; 1:3,000; cat. no. 7074; Cell Signaling Technology, Inc.; anti-mouse IgG; 1:3,000; cat. no. 7076; Cell Signaling Technology, Inc.) for 2 h at room temperature. The following primary antibodies were used in this study: Anti-CDC20 ( MTT assay. Cells were seeded in 96-well plates (A431, 5x10 3 cells/well; Scl-1, 3x10 3 cells/well; and SCC13, 5x10 3 cells/well) in quintuplicate and transfected with the negative control siRNA, CDC20 siRNA, HA-CDC20 plasmid or empty control plasmid the following day. Relative cell numbers were measured 24, 48 or 72 h subsequently by incubating cells with 20 µl 0.5 mg/ml MTT at 37˚C for 4 h. Following complete removal of the medium, 150 µl dimethyl sulfoxide was administrated to dissolve the formazan. The relative absorbance at a wavelength of 490 nm was measured with a microplate reader (model 680; Bio-Rad Laboratories, Inc.). A total of three independent experiments were performed. Meanwhile, cells were seeded in 96-well plates and treated with different concentrations of ATRA (cat. no. R2625; Sigma-Aldrich; Merck KGaA; 1, 10, 20, 40, 60, 80, 100 and 120 µM) the following day. Relative cell numbers were measured 48 h after ATRA treatment using the aforementioned method. A total of three independent experiments were performed.
Cell cycle analysis. The siRNA-transfected cells were harvested 48 h after transfection. For the analysis, cells were harvested, fixed with ice-cold 70% ethanol overnight, and stored overnight at -4˚C. The cells were stained with the Cell Cycle Detection kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China), and incubated for 30 min in the dark at room temperature, according to the manufacturer's protocol. The cells were analyzed using flow cytometry (FACSCalibur; BD Biosciences, San Diego, CA, USA). ModFit LT™ V3.3 (Verity Software House, Inc., Topsham, ME, USA) was used to analyze the results. A total of three independent experiments were performed.
Cell apoptosis analysis. The siRNA-transfected cells were harvested 48 h after transfection. For the analysis, the cells were stained with the Annexin V-fluorescein isothiocyanate/propidium iodide (PI) Apoptosis Detection kit (KeyGEN Biotech, Nanjing, China), following the manufacturer's instructions. Stained cells were analyzed by flow cytometry (FACSCalibur; BD Biosciences). FlowJo 10 (FlowJo LLC, Ashland, OR, USA) was used to analyze the results. A total of three independent experiments were performed.
Wound-healing assay. Cells were seeded into six-well plates (A431, 5x10 5 cells/well; Scl-1, 3x10 5 cells/well) and transfected with the negative control siRNA or CDC20 siRNA the following day. A total of 48 h after transfection, wounds were created in the cell monolayer using a 200 µl pipette tip. Cell debris was removed by washing once with PBS, followed by the addition of fresh DMEM containing 1% fetal bovine serum. The healing process was followed for the next 72 h.
Immunofluorescent staining. Cells were grown on glass coverslips. Following fixing with 4% paraformaldehyde at room temperature for 30 min, permeabilization with 0.5% Triton X-100 and blocking with 5% bovine serum albumin (Thermo Fisher Scientific., Inc.) for 1 h at room temperature, Table I . Sequences of the siRNAs used in the present study. the cells were incubated with primary antibodies against β-catenin (1:100, cat. no. 8480; Cell Signaling Technology, Inc.) at 4˚C overnight. Subsequently, the cells were incubated with the appropriate goat anti-rabbit IgG2 secondary antibody at room temperature for 1 h in the dark. The nuclei were counterstained with DAPI for 10 min at room temperature and imaged with a confocal laser-scanning microscope (magnification, x200) (Nikon Corporation, Tokyo, Japan).
Statistical analysis. Data are presented as the mean ± standard deviation. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). The Student's t-test was used for comparisons between two groups, and one-way analysis of variance with Dunnett's or Bonferroni's post hoc test was applied for experiments with more than two groups. P<0.05 was considered to indicate a statistically significant difference.
Results

CDC20 is significantly upregulated in cSCC tumor tissues and cSCC cell lines.
The analysis results from GEO2R for GSE32628 and GSE45216 are presented in Fig. 1A . In GSE32628, the mRNA expression values of CDC20 were 10.02±0.31 in normal skin tissues (n=13), 10.56±0.55 in AK tissues (n=13) and 11.17±0.74 in cSCC tissues (n=13). The CDC20 mRNA expression level was significantly higher in AK and cSCC tumor tissues compared with paired normal skin tissues (Fig. 1A) . In GSE45216, the mRNA expression values of CDC20 were 6.74±0.63 in the AK group (n=10), 7.89±1.35 in the well-differentiated cSCC group (n=15) and 8.56±0.99 in the moderately/poorly differentiated cSCC group (n=15). CDC20 expression was significantly increased in well-differentiated cSCC and moderately/poorly differentiated cSCC compared with AK (Fig. 1A) . Along with the results of the bioinformatics analysis, the immunohistochemical staining in 21 paired cSCC and corresponding normal tissues confirmed the elevated CDC20 expression in cancerous tissues (Fig. 1B and C) . In addition, compared with the primary human epidermal keratinocytes, CDC20 was upregulated in cSCC cell lines A431, SCL-1 and SCC13 at the mRNA (data not shown) and protein level (Fig. 1D) . Furthermore, the expression of CDC20 protein was detected in 144 samples from patients with cSCC at different stages, including normal skin tissues (n=32), precancerous actinic keratosis lesions (n=31), cSCC in situ (n=27), well-differentiated cSCC (n=29) and moderately/poorly differentiated cSCC (n=25). Subsequent semiquantitative analysis of the immunohistochemistry results demonstrated that CDC20 expression was significantly higher in cSCC in situ, well-differentiated cSCC, and moderately/poorly differentiated cSCC compared with normal skin, and was associated with disease progression (Fig. 2) . The findings indicated that CDC20 may have an oncogenic role in cSCC progression.
CDC20 silencing inhibits the proliferation of cSCC cells and leads to cell cycle arrest.
Compared with normal human epidermal keratinocytes, all the cSCC cell lines has increased CDC20 protein expression levels (Fig. 1D) ; however, among the three cSCC cell lines, SCC13 had the lowest basal level of CDC20. To test the potential oncogenic effects of CDC20, CDC20 was downregulated in Scl-1 and A431 cells, and overexpressed in SCC13. CDC20 silencing suppressed the growth of A431 and Scl-1 cells, as determined by the MTT assay ( Fig. 3A and B) . Transfection of HA-tagged CDC20 led to an increased total level of CDC20 protein and promoted the growth of SCC13 cells (Fig. 3C) . Cell cycle analysis demonstrated that CDC20 depletion led to cells accumulating in the G2/M phase ( Fig. 3D and E) and an increased expression level of cyclin B1 and cyclin A (Fig. 3F) , suggesting arrest in early mitosis.
CDC20 silencing promotes apoptosis and inhibits migration in cSCC in vitro.
Annexin V/PI staining was performed to detect apoptosis. Non-transfected or control siRNA-transfected cells exhibited a lower apoptosis rate of 11-12% in A431 and 6-7% in SCL-1 cells compared with the increased apoptosis rate of 12-16% in A431 and 9-12% in Scl-1 cells following CDC20 silencing (Fig. 4A and B) . The increased apoptosis was associated with increased expression of the apoptosis-promoting gene Bax and decreased expression of the apoptosis-suppressing gene Bcl-2 (Fig. 4C) . These results demonstrated that CDC20 was involved in protecting cSCC cells against apoptosis and that depletion of CDC20 induced apoptosis. In addition, to analyze whether CDC20 was able to inhibit the motility of cSCC cells, wound healing assays were performed. The results demonstrated that silencing of CDC20 decreased cell migration in A431 and Scl-1 cells (Fig. 5) .
Loss of CDC20 suppresses the Wnt/β-catenin signaling pathway. To understand the molecular mechanisms of the oncogenic effects of CDC20, the Wnt/β-catenin signaling pathway, one of the principal signaling pathways involved in the regulation of cell growth, survival and migration, was analyzed. The present results indicated that CDC20 silencing led to a reduced expression level of β-catenin and c-Myc (Fig. 6A and B) . In line with this, the immunofluorescence results indicated CDC20 that silencing led to decreased fluorescence and less distribution of β-catenin in the nucleus (Fig. 6C and D) , which indicated that the translocation of β-catenin into the nucleus was also inhibited by CDC20 knockdown. These results confirmed that CDC20 contributes to the growth of cSCC cells by activating the Wnt/β-catenin signaling pathway.
ATRA treatment downregulates CDC20 and β-catenin expression in cSCC cells.
To determine the suppressive effects of ATRA on cSCC cells, the MTT assay was conducted. The results demonstrated that ATRA decreased the viability of A431 and SCL-1 cells in a concentration-dependent manner (Fig. 7A) . To examine whether the CDC20/β-catenin pathway was involved in ATRA-induced growth inhibition, western blot analysis was used to detect CDC20 and β-catenin expression in cSCC cells following ATRA treatment for 48 h. The results demonstrated that ATRA treatment reduced the CDC20 and β-catenin protein expression in A431 and Scl-1 cells (Fig. 7B) .
Discussion
In recent years, the overexpression of CDC20 has been documented in a wide range of malignancies. In a number of tumor types, its expression has been reported to correlate with a poor clinical outcome, providing evidence for its role in carcinogenesis and tumor progression (10) (11) 13) . However, the role of CDC20 in primary cSCC has not been previously reported, to the best of our knowledge. In the present study, it was demonstrated that CDC20 is overexpressed in cSCC tissues in addition to cSCC cell lines, and its expression is associated with tumor progression. Knockdown of CDC20 suppressed cell growth and migration, and promoted apoptosis and cell cycle arrest in cSCC. Similar to what has been observed in other tumor types (9), CDC20 expression was low in normal intact skin and was significantly increased in tumor cells in cSCC, suggesting that CDC20 may work as a biomarker for cSCC. Furthermore, the elevated expression of CDC20 in AK and cSCC in situ, and its association with histological classification, provide evidence that the induction of CDC20 expression is an early event in cSCC development and may serve a role in the progression of in situ cSCC to the invasive stage. However, there were no follow-up data for the patients in the present study, thus it was not possible to draw any conclusion about the prognostic value of CDC20. CDC20 was overexpressed in SCC13 cells since this was the cell line with the lowest basal level of CDC20. When SCC13 was first established in 1981, it was identified that its colony formation efficiency was low and in a nude mouse model it tended to form large differentiating cysts with an organized structure, which is a pathological sign of good differentiation (22, 23) . Therefore SCC13 was considered to be a well-differentiated cSCC cell line in the present study. The immunohistochemistry results demonstrated that CDC20 was not only elevated in cancerous tissues, but was also associated with tumor differentiation and progression. The low basal protein level of CDC20 may, on the other hand, support the well-differentiated classification of SCC13. Therefore, the overexpression experiment was conducted to see whether CDC20 was able to induce malignancy, and the present results demonstrated that overexpression of CDC20 slightly increased the growth of SCC13 cells.
CDC20 is known to regulate the separation of chromosomes by inducing ubiquitination and the degradation of cell cycle regulators, including cyclin A and cyclin B1 in a D-box dependent manner at the beginning of metaphase, loss of CDC20 results in the accumulation of cyclin B1 and cyclin A (15) . While the degradation of cyclin B induces exit from mitosis (telophase and cytokinesis) (16), non-degradable cyclin B1 may arrest human cells in a metaphase-like state (17, 24) . CDC20 mutation/depletion blocks cell division and stops cell cycle progression toward anaphase and chromosome segregation (25) . Consistent with this report, it was observed in the present study that CDC20 knockdown inhibited the proliferation of cSCC cells and led to G2/M cell cycle arrest. CDC20 depletion induces the expression of cyclin A and cyclin B1 (24, 26) , and exogenous expression of CDC20 slightly increased the growth of SCC13 cells in the present study. Similarly, a recent study confirmed that the overexpression of CDC20 promoted cell growth, inhibited apoptosis, and enhanced cell migration and invasion in osteosarcoma cells (27) . In addition, it was reported that CDC20 may control mitotic progression by targeting a number of novel substrates, including ubiquitin interaction motif containing 1, PHD finger protein 8 and BRCA1 associated RING domain 1 (28, 29) . These findings support the hypothesis that CDC20 serves a crucial role in cell cycle regulation.
In addition to G2/M phase arrest, the present data demonstrated that the inhibition of CDC20 activity led to the induction of apoptosis. CDC20 depletion increased the expression of Bax and reduced the expression of Bcl-2. Similar regulation of apoptosis by CDC20 has been observed in other studies. For example, in multiple tumor-derived cell lines, Bcl-2 like 11 accumulation upon CDC20 knockdown contributes to apoptosis induction and chemoradiation sensitization (30) . Another study suggested that CDC20 governs apoptosis by mediating the degradation of the anti-apoptotic protein induced myeloid leukemia cell differentiation protein Mcl- (31) . Furthermore, it was demonstrated that CDC20 regulated the migratory ability of cSCC cells. This finding is consistent with the results from a previous study, demonstrating that CDC20 expression was further increased in matched metastatic liver tissues compared with primary colorectal cancer tissues (13) .
Wnt signaling through β-catenin has long been recognized to be crucial for skin epidermal development and homeostasis (32) . A number of studies have confirmed that it is essential for cSCC initiation and progression, and for maintaining the cancer stem cell niche (33) . Based on the primary hypothesis that targeting CDC20 may improve the aggressive properties of cSCC, the present study sought to investigate whether this process was associated with suppression of the canonical Wnt/β-catenin pathway. Wnt/β-catenin is a well-known pathway that is involved in the progression of cSCC. Recently, Zimmerli et al (33) reported that the Wnt/β-catenin pathway controlled the initiation and progression of human papillomavirus-driven cSCC. Although the effect of stimulation of Wnt/β-catenin on the cellular behavior of cSCC was not assessed in the present study, β-catenin and c-Myc, which are classically important components involved in the Wnt/β-catenin signaling pathway, were tested following silencing of CDC20. The present results demonstrated that CDC20 silencing led to a significantly decreased protein expression level of β-catenin and c-Myc, and inhibited the translocation of β-catenin into the nucleus, suggesting that CDC20 contributes to the development of cSCC through the Wnt/β-catenin signaling pathway. However, there were a number of limitations to the signaling pathway analysis. First, the role of other proteins involved in the Wnt/β-catenin pathway, including adenomatous polyposis coli protein, axin and zinc finger protein SNAI1 were not tested in the present study. Second, it was not possible to ascertain whether β-catenin is the substrate of the APC/C-CDC20 complex.
Retinoids have long been considered for use in the treatment and prevention of cancer (34, 35) . The present finding that ATRA was able to inhibit cSCC cell growth was consistent with the results reported by Zhang et al (36) . The fact that ATRA was able to downregulate the expression of CDC20 indicates that CDC20 may work as a potential therapeutic target in cSCC. It was noted that the cell killing effect of ATRA was marked at ~60 µM, a relatively high concentration. However, the majority of retinoids are available for topical use, which means that they may be able to work directly and specifically on skin cancer lesions. Severe side effects of topical retinoids are very rare despite their high concentrations (for example, 0.1% adapalene gel) (37) . Thus, for patients with a localized AK or cSCC in situ, topical retinoids may be beneficial. Meanwhile, discovering and validating small molecule inhibitors specifically targeting CDC20 remains critical for future studies. It is noteworthy that a recent study demonstrated that the systemic use of CDC20 siRNA was able to inhibit solid growths of subcutaneously injected melanoma and spontaneous growth of intravenously injected melanoma cells on the mouse lung (38) . Therefore, CDC20 is a promising target for the treatment of human cancer.
In conclusion, the present results demonstrated that CDC20 serves a carcinogenic role in human cSCC, and may therefore serve as a novel target for early prevention, diagnosis and treatment. 
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